Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075324 | 0.80 | LTB4R (0.44) | LTB4RLTB4R2FFAR1HTR6DRD2 | |
| SCHEMBL23949380 | 0.79 | LTB4R (0.41) | LTB4RLTB4R2 | |
| SCHEMBL8282396 | 0.79 | CA2 (0.59) | CA2FFAR1POLBESR2HTR6 | |
| SCHEMBL5917900 | 0.78 | CA2 (0.42) | CA2POLBESR2HTR6MTNR1A | |
| SCHEMBL17150883 | 0.78 | CA2 (0.51) | CA2FFAR1POLBESR2HTR6 | |
| SCHEMBL23775858 | 0.78 | ALDH1A1 (0.49) | LTB4RLTB4R2POLB | |
| SCHEMBL16089590 | 0.78 | CA2 (0.58) | CA2FFAR1DRD2DRD4DRD3 | |
| SCHEMBL24630678 | 0.75 | LTB4R (0.39) | LTB4RLTB4R2 | |
| SCHEMBL21533920 | 0.75 | CHRNB4 (0.41) | — | |
| SCHEMBL24257142 | 0.75 | LTB4R (0.38) | LTB4RLTB4R2FFAR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | LTB4R 3577/4885LTB4R2 3761/4885CA2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.